首页> 外文期刊>Journal of Medicinal Chemistry >4-(phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4)
【24h】

4-(phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4)

机译:4-(苯基氨基亚甲基)异喹啉-1,3(2H,4H)-二酮类是细胞周期蛋白依赖性激酶4(CDK4)的有效抑制剂

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The cyclin-dependent kinases (CDKs), as complexes with their respective partners, the cyclins, are critical regulators of cell cycle progression. Because aberrant regulations of CDK4/cyclin D1 lead to uncontrolled cell proliferation, a hallmark of cancer, small-molecule inhibitors of CDK4/cyclin D1 are attractive as prospective antitumor agents. The series of 4-(phenylaminomethylene)isoquinoline-1,3(2H,4H)-dione derivatives reported here represents a novel class of potent inhibitors that selectively inhibit CDK4 over CDK2 and CDK1 activities. In the headpiece of the 4-(phenylaminomethylene)isoquinoline-1,3(2H,4H)dione, a basic amine substitutent is required on the aniline ring for the CDK4 inhibitory activity. The inhibitory activity is further enhanced when an aryl or heteroaryl substituent is introduced at the C-6 position of the isoquinoline-1,3(2H,4H)-dione core. We present here SAR data and a CDK4 mimic model that explains the binding, potency, and selectivity of our CDK4 selective inhibitors.
机译:细胞周期蛋白依赖性激酶(CDK)与它们各自的伴侣细胞周期蛋白形成复合物,是细胞周期进程的关键调节剂。由于CDK4 / cyclin D1的异常调控导致不受控制的细胞增殖,这是癌症的标志,因此CDK4 / cyclin D1的小分子抑制剂作为前瞻性抗肿瘤药很有吸引力。本文报道的一系列4-(苯基氨基亚甲基)异喹啉-1,3(2H,4H)-二酮衍生物代表了一类新型的有效抑制剂,该抑制剂选择性抑制CDK4超过CDK2和CDK1活性。在4-(苯基氨基亚甲基)异喹啉-1,3(2H,4H)二酮的头戴剂中,苯胺环上需要碱性胺取代基来抑制CDK4。当在异喹啉-1,3(2H,4H)-二酮核心的C-6位引入芳基或杂芳基取代基时,抑制活性会进一步增强。我们在这里介绍了SAR数据和一个CDK4模拟模型,该模型解释了我们的CDK4选择性抑制剂的结合,效价和选择性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号